American Academy of Ophthalmology pushed back against pressure to use bevacizumab biosimilars off-label

Jul 29, 2021

The American Academy of Ophthalmology pushed back against insurance company pressure to use new bevacizumab biosimilars off-label in eye treatment as alternatives to Avastin® (bevacizumab) in the absence of supporting studies.

Print Page Mail Article